This trial is testing a new medication (Bmab 1000) to see how it compares to an existing medication (Prolia®) in terms of how it is processed by the body, how it affects the body, and how safe and tolerable it is.
3 Primary · 11 Secondary · Reporting Duration: 0 to 36 week
Active Control
Experimental Treatment
190 Total Participants · 2 Treatment Groups
Primary Treatment: Bmab 1000 · No Placebo Group · Phase 1
Participation is compensated
You will be compensated for participating in this trial.
Age 28 - 55 · Male Participants · 6 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Massachusetts | 100.0% |
65+ | 100.0% |
Biotrial Inc | 100.0% |
Met criteria | 100.0% |